Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 218

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues

Open access
Wang, Wang, McKinnie, Shaun M.K., Patel, Vaibhav B., Haddad, George, Wang, Zuocheng, Zhabyeyev, Pavel, Das, Subhash K., Basu, Ratnadeep, McLean, Brent, Kandalam, Vijay, Penninger, Josef M., Kassiri, Zamaneh, Vederas, John C., Murray, Allan G., Oudit, Gavin Y. · 2013 · Journal of the American Heart Association

Abstract

Background: Coronary artery disease leading to myocardial ischemia is the most common cause of heart failure. Apelin ( APLN ), the endogenous peptide ligand of the APJ receptor, has emerged as a novel regulator of the cardiovascular system. Methods and Results: Here we show a critical role of APLN in myocardial infarction ( MI ) and ischemia‐reperfusion ( IR ) injury in patients and animal models. Myocardial APLN levels were reduced in patients with ischemic heart failure. Loss of APLN increased MI ‐related mortality, infarct size, and inflammation with drastic reductions in prosurvival pathways resulting in greater systolic dysfunction and heart failure. APLN deficiency decreased vascular sprouting, impaired sprouting of human endothelial progenitor cells, and compromised in vivo myocardial angiogenesis. Lack of APLN enhanced susceptibility to ischemic injury and compromised functional recovery following ex vivo and in vivo IR injury. We designed and synthesized two novel APLN analogues resistant to angiotensin converting enzyme 2 cleavage and identified one analogue, which mimicked the function of APLN , to be markedly protective against ex vivo and in vivo myocardial IR injury linked to greater activation of survival pathways and promotion of angiogenesis. Conclusions: APLN is a critical regulator of the myocardial response to infarction and ischemia and pharmacologically targeting this pathway is feasible and represents a new class of potential therapeutic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.113.000249

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 218

Metadata

Authors
Wang, W., McKinnie, S. M. K., Patel, V. B., Haddad, G., Wang, Z., Zhabyeyev, P., Das, S. K., Basu, R., McLean, B., Kandalam, V., Penninger, J. M., Kassiri, Z., Vederas, J. C., Murray, A. G., & Oudit, G. Y.
Venue
Journal of the American Heart Association
Published
2013-08-22
Volume
2
Issue
4
Pages
e000249-e000249
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2130674647
Cited by
218
References
4
FWCI
13.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. https://app.cochat.ai/papers/10.1161/jaha.113.000249
The paper
Wang, W., McKinnie, S. M. K., Patel, V. B., Haddad, G., Wang, Z., Zhabyeyev, P., Das, S. K., Basu, R., McLean, B., Kandalam, V., Penninger, J. M., Kassiri, Z., Vederas, J. C., Murray, A. G., & Oudit, G. Y. (2013). Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. Journal of the American Heart Association. https://doi.org/10.1161/jaha.113.000249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.